|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12...345678910111213...4950» |
- Trial suspension, Trial primary completion date: Pilot Study of Diflunisal in HIV-infected Adults (clinicaltrials.gov) - Jun 20, 2016
P4, N=20, Suspended, Sponsor: University of British Columbia
Recruiting --> Suspended | Trial primary completion date: Mar 2016 --> Dec 2016
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jun 20, 2016
P4, N=10, Active, not recruiting, Sponsor: University of British Columbia
Recruiting --> Suspended | Trial primary completion date: Mar 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- | naltrexone / Generic mfg.
Enrollment closed: Clinical Trial to Reduce Drinking in Women With HIV (clinicaltrials.gov) - Jun 20, 2016
P3, N=240, Active, not recruiting, Sponsor: University of Florida
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: SUAT: Switch to Unboosted Atazanavir With Tenofovir Study (clinicaltrials.gov) - Jun 20, 2016
P4, N=50, Completed, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jan 2015
- Trial completion, Enrollment change, HEOR, Cost effectiveness: Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=153, Completed, Sponsor: George Washington University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jan 2015 Active, not recruiting --> Completed | N=100 --> 153
- || Enrollment closed, Adherence: SPARK: Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting (clinicaltrials.gov) - Jun 15, 2016
P=N/A, N=445, Active, not recruiting, Sponsor: Hunter College
Active, not recruiting --> Completed | N=100 --> 153 Recruiting --> Active, not recruiting
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment closed, Enrollment change: Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy (clinicaltrials.gov) - Jun 15, 2016
P1/2, N=25, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=65 --> 25
- | Trial completion: Preventive Therapy for Tuberculosis in HIV Infected Persons (clinicaltrials.gov) - Jun 11, 2016
P3, N=650, Completed, Sponsor: Tuberculosis Research Centre, India
Recruiting --> Active, not recruiting | N=65 --> 25 Active, not recruiting --> Completed
- Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Jun 10, 2016
P2b, N=71, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b | N=471 --> 71 | Trial primary completion date: Sep 2016 --> Feb 2016
- Trial completion, Enrollment change, Trial primary completion date: The Use of Peer Referral Incentives to Increase Demand for Voluntary Medical Male Circumcision in Zambia (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=725, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2b | N=471 --> 71 | Trial primary completion date: Sep 2016 --> Feb 2016 Active, not recruiting --> Completed | N=21259 --> 725 | Trial primary completion date: Feb 2015 --> Sep 2015
- |||| darunavir/ritonavir / Generic mfg.
Trial completion: DUAL: Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject (clinicaltrials.gov) - Jun 5, 2016
P4, N=249, Completed, Sponsor: Fundacion SEIMC-GESIDA
Active, not recruiting --> Completed | N=21259 --> 725 | Trial primary completion date: Feb 2015 --> Sep 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects (clinicaltrials.gov) - Jun 5, 2016
P1, N=12, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015
- |||| lamivudine / Generic mfg.
Trial primary completion date, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Jun 5, 2016
P3, N=265, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015 Trial primary completion date: Dec 2016 --> Apr 2016
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Trial initiation date: HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection (clinicaltrials.gov) - Jun 5, 2016
P1, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Dec 2016 --> Apr 2016 Initiation date: Mar 2016 --> Sep 2016
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) - Jun 2, 2016
P2, N=150, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Mar 2016 --> Sep 2016 Recruiting --> Active, not recruiting
- GTU-multi-HIV B clade DNA vaccine / ValiRx
Trial completion: Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers (clinicaltrials.gov) - Jun 1, 2016
P1/2, N=92, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Adherence: dPEP: The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (clinicaltrials.gov) - May 27, 2016
P4, N=100, Completed, Sponsor: Andrew Carr
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Enhancement of Connect to Protect (clinicaltrials.gov) - May 26, 2016
P=N/A, N=927, Completed, Sponsor: Westat
Active, not recruiting --> Completed Recruiting --> Completed | N=4185 --> 927
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change: Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir (clinicaltrials.gov) - May 26, 2016
P2, N=11, Completed, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting --> Completed | N=4185 --> 927 Recruiting --> Completed | N=25 --> 11
- Trial completion, Enrollment change: Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention (clinicaltrials.gov) - May 26, 2016
P=N/A, N=650, Completed, Sponsor: Westat
Recruiting --> Completed | N=25 --> 11 Recruiting --> Completed | N=1550 --> 650
- ||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment change: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - May 24, 2016
P3, N=55, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed | N=1550 --> 650 N=100 --> 55
- Trial completion, Trial primary completion date: OCTIHIV: Revealing Increased Axonal Loss in Treated HIV Patients (clinicaltrials.gov) - May 20, 2016
P=N/A, N=156, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
N=100 --> 55 Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2015
- dipyridamole / Generic mfg.
Trial primary completion date, IO biomarker: Dipyridamole for Immune Activation in HIV (clinicaltrials.gov) - May 16, 2016
P1/2, N=40, Recruiting, Sponsor: Sharon Riddler
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Aug 2015 Trial primary completion date: Aug 2016 --> Dec 2017
- ||||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment closed: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - May 13, 2016
P2/3, N=90, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Aug 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- Trial completion: PARC: Pre-ART Retention in Care in Tanzania (clinicaltrials.gov) - May 13, 2016
P=N/A, N=948, Completed, Sponsor: Columbia University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - May 13, 2016
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Mar 2017
- mupirocin / Generic mfg.
Trial primary completion date: Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons (clinicaltrials.gov) - May 13, 2016
P=N/A, N=550, Active, not recruiting, Sponsor: Uniformed Services University of the Health Sciences
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- | valacyclovir / Generic mfg.
Trial completion, Trial primary completion date: VALIANT Pilot: Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? (clinicaltrials.gov) - May 13, 2016
P3, N=60, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Aug 2013
- Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: RALBAT: Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (clinicaltrials.gov) - May 12, 2016
P4, N=66, Recruiting, Sponsor: Giovanni Di Perri
Recruiting --> Completed | Trial primary completion date: Jun 2011 --> Aug 2013 Trial primary completion date: Mar 2016 --> Dec 2016
- Trial completion, Observational data, Trial primary completion date: Progress Adult Study (clinicaltrials.gov) - May 12, 2016
P=N/A, N=5600, Completed, Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Trial primary completion date: Mar 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Jun 2015
- zoledronic acid / Generic mfg.
Trial primary completion date: Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV) (clinicaltrials.gov) - May 11, 2016
P2, N=78, Active, not recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Jun 2015 Trial primary completion date: Apr 2016 --> Apr 2017
- methamphetamine / Generic mfg.
Enrollment closed, Trial primary completion date: Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users (clinicaltrials.gov) - May 11, 2016
P=N/A, N=450, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- Trial completion: WSW: Sexually Transmitted Infections Among African American Women Who Have Sex With Women (clinicaltrials.gov) - May 11, 2016
P=N/A, N=300, Completed, Sponsor: University of Mississippi Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Suspended --> Completed
- ||| Trial completion, HEOR: The Psychosocial and Economic Burden of Genital Warts (clinicaltrials.gov) - May 10, 2016
P=N/A, N=224, Completed, Sponsor: BEMFAM-Bem Estar Familiar
Suspended --> Completed Not yet recruiting --> Completed
- |||| Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion: Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR) (clinicaltrials.gov) - May 9, 2016
P2a, N=127, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Lactoferrin Treatment in HIV Patients (clinicaltrials.gov) - May 5, 2016
P2, N=50, Recruiting, Sponsor: Jason Baker
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment change: Maraviroc Compassionate Use (clinicaltrials.gov) - May 4, 2016
P3, N=0, Withdrawn, Sponsor: ViiV Healthcare
Trial primary completion date: Mar 2016 --> Dec 2016 N=30 --> 0
- Trial primary completion date, HEOR: Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Wayne State University
N=30 --> 0 Trial primary completion date: May 2016 --> Sep 2016
- Trial completion: LINC: Linking Infectious and Narcology Care in Russia (clinicaltrials.gov) - Apr 27, 2016
P=N/A, N=349, Completed, Sponsor: Boston Medical Center
Trial primary completion date: May 2016 --> Sep 2016 Active, not recruiting --> Completed
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial primary completion date: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Apr 21, 2016
P2, N=360, Active, not recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Sep 2015
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial primary completion date: Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (clinicaltrials.gov) - Apr 20, 2016
P3, N=1805, Completed, Sponsor: Anna Griffiths, MRC
Trial primary completion date: Mar 2016 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2016
- Trial completion, Enrollment change: CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC) (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=112, Completed, Sponsor: George Washington University
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2016 Recruiting --> Completed | N=150 --> 112
- | Trial completion: Retrovirus Epidemiology Donor Study-II (REDS-II) (clinicaltrials.gov) - Apr 13, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=150 --> 112 No longer recruiting --> Completed
- | Trial completion: Retrovirus Epidemiology Donor Study I (REDS I) (clinicaltrials.gov) - Apr 13, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed No longer recruiting --> Completed
- Trial primary completion date: Screening, Brief Intervention, and Referral to Treatment for Offenders (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=800, Active, not recruiting, Sponsor: University of California, Los Angeles
No longer recruiting --> Completed Trial primary completion date: Mar 2016 --> Mar 2017
- Trial primary completion date: TLCIDU Kenya: Testing and Linkage to Care for Injecting Drug Users in Kenya (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=4500, Recruiting, Sponsor: Yale University
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> Apr 2016
- Trial completion, Trial initiation date, Trial primary completion date, Adherence: Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=40, Completed, Sponsor: RAND
Trial primary completion date: Dec 2015 --> Apr 2016 Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Apr 2013 | Trial primary completion date: Dec 2014 --> Nov 2015
- Trial completion: Fish Oil for HIV-Related Inflamm-aging and Immune Senescence (clinicaltrials.gov) - Apr 7, 2016
P2, N=38, Completed, Sponsor: Rush University Medical Center
Not yet recruiting --> Completed | Initiation date: Aug 2014 --> Apr 2013 | Trial primary completion date: Dec 2014 --> Nov 2015 Recruiting --> Completed
- Trial completion, Enrollment change: Eliciting Affect in Teens in a Virtual World (Project AVATAR) (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=196, Completed, Sponsor: Rhode Island Hospital
Recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 196
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment closed, Trial primary completion date: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - Apr 4, 2016
P=N/A, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | N=100 --> 196 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2016